1. Home
  2. SNTI vs ZDAI Comparison

SNTI vs ZDAI Comparison

Compare SNTI & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.35

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

ZDAI

Primega Group Holdings Limited Ordinary Shares

HOLD

Current Price

$1.60

Market Cap

13.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTI
ZDAI
Founded
2016
2022
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
General Bldg Contractors - Nonresidential Bldgs
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
13.6M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
SNTI
ZDAI
Price
$0.35
$1.60
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
185.1K
47.0K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
77.31
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.20
52 Week High
$2.88
$11.48

Technical Indicators

Market Signals
Indicator
SNTI
ZDAI
Relative Strength Index (RSI) 35.26 40.32
Support Level $0.33 $1.59
Resistance Level $0.40 $2.04
Average True Range (ATR) 0.04 0.12
MACD 0.01 0.00
Stochastic Oscillator 13.39 32.08

Price Performance

Historical Comparison
SNTI
ZDAI

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

Share on Social Networks: